📣 VC round data is live. Check it out!

FluoGuide Valuation Multiples

Discover revenue and EBITDA valuation multiples for FluoGuide and similar public comparables like Senzime, Medicalgorithmics, Applied BioCode, Vuno and more.

FluoGuide Overview

About FluoGuide

FluoGuide AS is a clinical-stage biotechnology company focused on developing drugs that maximize surgical outcomes by making cancer fluorescent. Its technology includes uPAR, which is part of a proteolytic system, and FG001, a product injected into the patient's vein prior to surgery.


Founded

2018

HQ

Denmark

Employees

8

Financials (LTM)

Revenue: -
EBITDA: ($7M)

EV

$72M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

FluoGuide Financials

FluoGuide reported last 12-month revenue of - and negative EBITDA of ($7M).

In the same LTM period, FluoGuide generated - in gross profit, ($7M) in EBITDA losses, and had net loss of ($7M).

Revenue (LTM)


FluoGuide P&L

In the most recent fiscal year, FluoGuide reported revenue of - and EBITDA of ($6M).

FluoGuide is unprofitable as of last fiscal year, with EBITDA margin of - and net margin of -.

See analyst estimates for FluoGuide
LTMLast FY202320242025202620272028
EBITDA($7M)($6M)($7M)($5M)($7M)
Net Profit($7M)($6M)($6M)($5M)($6M)

Financial data powered by Morningstar, Inc.

FluoGuide Stock Performance

FluoGuide has current market cap of $78M, and enterprise value of $72M.

Market Cap Evolution


FluoGuide's stock price is $4.74.

FluoGuide share price decreased by 0.8% in the last 30 days, and increased by 8.8% in the last year.

FluoGuide has an EPS (earnings per share) of $-0.38.

See more trading valuation data for FluoGuide
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$72M$78M-0.8%-0.8%20.5%8.8%$-0.38

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

FluoGuide Valuation Multiples

FluoGuide trades at (10.7x) EV/EBITDA.

See NTM and 2027E valuation multiples for FluoGuide

FluoGuide Financial Valuation Multiples

As of June 2, 2026, FluoGuide has market cap of $78M and EV of $72M.

FluoGuide has a P/E ratio of (11.4x).

LTMLast FY202320242025202620272028
EV/EBITDA(10.7x)(11.6x)(10.6x)(13.6x)(10.4x)
EV/EBIT(10.5x)(11.6x)(10.5x)(14.0x)(11.6x)
P/E(11.4x)(12.6x)(13.0x)(17.2x)(12.6x)
EV/FCF-(12.5x)(14.5x)(15.4x)(12.5x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified FluoGuide Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

FluoGuide Margins & Growth Rates

FluoGuide grew EBITDA by 21% in the last fiscal year.

See estimated margins and future growth rates for FluoGuide

FluoGuide Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
EBITDA Growth21%(22%)31%9%
EBIT Growth23%(25%)21%23%
Net Profit Growth23%(25%)36%23%
FCF Growth-(6%)23%-

Data powered by FactSet, Inc. and Morningstar, Inc.

FluoGuide Operational KPIs

FluoGuide's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.8M for the same period.

Access forward-looking KPIs for FluoGuide
Last FY202620272028
Revenue per Employee$0.0M
Opex per Employee$0.8M

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

FluoGuide Competitors

FluoGuide competitors include Senzime, Medicalgorithmics, Applied BioCode, Vuno, Agfa-Gevaert, AnteoTech, Nexstim, Aiforia, BioStem Technologies and Pentixapharm Holding.

Most FluoGuide public comparables operate across Medical Devices, Medical Imaging & Diagnostics, BioTech, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Senzime6.2x5.3x(6.5x)(8.6x)
Medicalgorithmics12.3x7.7x(24.7x)242.9x
Applied BioCode4.2x-(13.8x)-
Vuno2.6x-(24.4x)-
Agfa-Gevaert0.2x0.2x3.1x3.1x
AnteoTech107.6x116.4x(20.2x)(32.2x)
Nexstim5.9x5.5x35.4x31.9x
Aiforia16.8x13.7x(9.9x)(12.1x)

This data is available for Pro users. Sign up to see all FluoGuide competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About FluoGuide

When was FluoGuide founded?FluoGuide was founded in 2018.
Where is FluoGuide headquartered?FluoGuide is headquartered in Denmark.
How many employees does FluoGuide have?As of today, FluoGuide has over 8 employees.
Is FluoGuide publicly listed?Yes, FluoGuide is a public company listed on Nasdaq Stockholm.
What is the stock symbol of FluoGuide?FluoGuide trades under FLUO ticker.
When did FluoGuide go public?FluoGuide went public in 2019.
Who are competitors of FluoGuide?FluoGuide main competitors include Senzime, Medicalgorithmics, Applied BioCode, Vuno, Agfa-Gevaert, AnteoTech, Nexstim, Aiforia, BioStem Technologies, Pentixapharm Holding.
What is the current market cap of FluoGuide?FluoGuide's current market cap is $78M.
Is FluoGuide profitable?No, FluoGuide is not profitable.
What is the current EBITDA of FluoGuide?FluoGuide has negative EBITDA and is not profitable.
What is the current EV/EBITDA multiple of FluoGuide?Current EBITDA multiple of FluoGuide is (10.7x).
How many companies FluoGuide has acquired to date?FluoGuide hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies FluoGuide has invested to date?FluoGuide hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to FluoGuide

Lists including FluoGuide

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial